ELMD
Electromed Inc
AMEX: ELMD · HEALTHCARE · MEDICAL DEVICES
$25.93
+2.64% today
Updated 2026-06-05
Market cap
$312.08M
P/E ratio
32.21
P/S ratio
4.35x
EPS (TTM)
$1.17
Dividend yield
—
52W range
$18 – $40
Volume
0.1M
WallStSmart proprietary scores
66
out of 100
Grade: B
Buy
Investment rating
8.7
Growth
A7.8
Quality
B+7.5
Profitability
B+5.3
Valuation
C+5/9
Piotroski F-Score
Moderate
5.6
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$40.33
+55.53%
12-Month target
$30.56
+17.86%
Intrinsic (DCF)
$15.46
Margin of safety
-63.39%
Price chart
Stock snapshot
Strengths
+ Altman Z 5.57 — safe zone
+ ROE 20.55% — strong efficiency
+ Free cash flow $3.33M — positive
+ Revenue growth 18.40% QoQ
Risks
- 63.39% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $41.66M | $48.07M | $54.72M | $64.00M | $71.75M |
| Net income | $2.31M | $3.17M | $5.15M | $7.54M | $3.00M |
| EPS | — | — | — | — | $1.17 |
| Free cash flow | $-2.21M | $-401000.00 | $8.67M | $11.09M | $3.33M |
| Profit margin | 5.53% | 6.59% | 9.41% | 11.78% | 14.10% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-15 | SKARVAN, KATHLEEN | Sale | 40,000 | — |
| 2026-05-15 | SKARVAN, KATHLEEN | Buy | 40,000 | $3.82 |
| 2026-05-15 | SKARVAN, KATHLEEN | Sale | 19,032 | $35.24 |
Peer comparison
Smart narrative
Electromed Inc trades at $25.93. representing a P/E of 32.21x trailing earnings. Our Smart Value Score of 66/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 5.57, it sits in the safe zone. TTM revenue stands at $71.75M. with profit margins at 14.10%. Our DCF model estimates intrinsic value at $15.46.
Frequently asked questions
What is Electromed Inc's stock price?
Electromed Inc (ELMD) trades at $25.93, on a P/E of 32.2x and a P/S of 4.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Electromed Inc overvalued?
Electromed Inc carries a Smart Value Score of 66/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $15.46 against the $25.93 price, so on cash flow terms the market is paying a premium for Electromed Inc's growth. The Buy rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Electromed Inc (ELMD)?
The 12-month analyst consensus target is $40.33, about 55.5% above the current $25.93. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Electromed Inc (ELMD)?
Our DCF model estimates intrinsic value at $15.46, a -63.4% margin of safety versus today's $25.93. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Electromed Inc's revenue?
Electromed Inc's trailing twelve-month revenue is $71.75M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Electromed Inc's Altman Z-Score is 5.57, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeAMEX
CurrencyUSD
Quick metrics
P/S ratio4.35x
ROE20.55%
Beta0.52
50D MA$28.82
200D MA$26.44
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—